ArticleCureus2026
Severe Hyperferritinemia in Metabolic Dysfunction-Associated Steatotic Liver Disease With Normal Transferrin Saturation and Polyclonal Hypergammaglobulinemia Mimicking Iron Overload.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic immunometabolic disorder characterized by the interplay between insulin resistance, hepatic lipid accumulation, and chronic low-grade inflammation. While mild elevations in serum ferritin are frequently observed in MASLD, markedly elevated ferritin levels often prompt evaluation for iron overload syndromes, inflammatory disorders, or malignancy. The coexistence of polyclonal hypergammaglobulinemia further complicates diagnostic interpretation. We report a 36-year-old female with overweight status, insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR) = 6.3), prediabetes (glycosylated hemoglobin = 6.1%), hypertriglyceridemia, and hyperuricemia, who demonstrated persistent hyperferritinemia (1281-1642 ng/mL) over 19 months with normal transferrin saturation (23%). Liver enzymes were mildly elevated, while bilirubin, gamma-glutamyl transferase, lactate dehydrogenase, C-reactive protein, and renal function remained normal. Serum protein electrophoresis revealed polyclonal hypergammaglobulinemia with elevated IgG. Imaging confirmed severe hepatic steatosis (S3) without fibrosis. MRI-based liver iron quantification demonstrated normal liver iron concentration (LIC = 2.70 mg/g), definitively excluding iron overload. Extensive evaluation excluded iron overload, autoimmune disease, and hematologic pathology. This case illustrates a clinically important pattern within MASLD in which hyperferritinemia reflects inflammatory signaling and iron sequestration rather than iron overload. Recognition of this phenotype enables confident diagnosis and prevents unnecessary investigations and inappropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.